Effects of β-funaltrexamine on dose-effect curves for heroin self- administration in rats: Comparison with alteration of [3H]DAMGO binding to rat brain sections

Drug and Alcohol Dependence

Volumn 52, Issue 2, 1998, Pages 135-147

  Martin, Thomas J ^a   Demontis, M Graziella ^b   Kim, Susy A ^a   Sizemore, Glen M ^a   Dworkin, Steven I ^a   Smith, James E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Institute of Pharmacology   (Italy)

Author keywords

Alkylation; Antagonism; Efficacy; Receptors; Reinforcement

Indexed keywords

BETA FUNALTREXAMINE; COCAINE; DIAMORPHINE;

ALKYLATION; ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; REINFORCEMENT;

ANALGESICS, OPIOID; ANIMALS; BRAIN; CAUDATE NUCLEUS; COCAINE; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALINS; HEROIN; HEROIN DEPENDENCE; MOTIVATION; NALTREXONE; NARCOTIC ANTAGONISTS; NUCLEUS ACCUMBENS; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, MU; SELF ADMINISTRATION;

ANIMALIA;

EID: 0032191131     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00082-9     Document Type: Article

References (41)

1. Adams J.U., Paronis C.A., Holtzman S.G. Assessment of relative intrinsic activity of μ opioid analgesics in vivo using β-funaltrexamine. J. Pharmacol. Exp. Ther. 255:1990;1027-1032.
2. Ator, N.A., 1991. Subjects and instrumentation. In: Experimental Analysis of Behavior. Part 1. Techniques in the Behavioral and Neural Sciences, vol. 6. Elsevier, New York, pp. 1-62.
3. Bozarth M.A. Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats. Brain Res. 414:1987;77-84.
4. Chan K., Brodsky M., Davis T., Franklin S., Inturrisi C.E., Yoburn B.C. The effect of the irreversible μ-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA. Eur. J. Pharmacol. 287:1995;135-143.
5. Chen X.H., Adams J.U., Geller E.B., DeRiel J.K., Adler M.W., Liu-Chen L.-Y. An antisense oligodeoxynucleotide to μ-opioid receptors inhibits μ-opioid receptor agonist-induced analgesia in rats. Eur. J. Pharmacol. 275:1995;105-108.
6. Dykstra L.A., Gmerek D.E., Woods J.H. Kappa opioid agonists in rhesus monkeys. II. Analysis of the antagonist actions of quadazocine and β-funaltrexamine. J. Pharmacol. Exp. Ther. 242:1987;421-427.
7. Ettenberg A., Pettit H.O., Bloom F.E., Koob G.F. Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systems. Psychopharmacologia. 78:1982;204-209.
8. Furchgott, R.F., 1955. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper, N.J., Simmons, A.B. (Eds.), Advances in Drug Research, vol. 3. Academic Press, London, pp. 13-39.
9. Heyman J.S., Jiang Q., Rothman R.B., Mosberg H.I., Porreca F. Modulation of μ-mediated antinociception by δ agonists: characterization with antagonists. Eur. J. Pharmacol. 169:1989;43-52.
10. Jiang Q., Heyman J.S., Sheldon R.J., Koslo R.J., Porreca F. Mu antagonist and kappa agonist properties of β- funaltexamine (β-FNA) in vivo: long-lasting spinal analgesia in mice. J. Pharmacol. Exp. Ther. 252:1990;1006-1011.
11. Kenakin, T., 1993b. Agonist affinity. In: Pharmacologic Analysis of Drug-receptor Interaction, 2nd ed. Raven Press, New York, pp. 221-248.
12. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
13. Koob G.F., Pettit H.O., Ettenberg A., Bloom F.E. Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat. J. Pharmacol. Exp. Ther. 229:1984;481-486.
14. Larson D.L., Hua M., Takemori A.E., Portoghese P.S. Possible contribution of a glutathione conjugate to the long-duration action of beta-funaltrexamine. J. Med. Chem. 36:1993;3669-3673.
15. 3H]β-funaltrexamine. Mol. Pharmacol. 32:1987;321-329.
16. 3H]β-funaltrexamine to opioid receptors in the rat forebrain: comparison with μ and δ opioid receptor distribution. Brain Res. 544:1991;235-242.
17. Liu-Chen L.-Y., Yang H.H., Li S., Adams J.U. Effect of intracerebroventricular beta-funaltrexamine on μ opioid receptors in the rat brain: consideration of binding condition. J. Pharmacol. Exp. Ther. 273:1995;1047-1056.
18. Mahan L.C., McKernan R.M., Insel P.A. Metabolism of alpha- and beta-adrenergic receptors in vitro and in vivo. Annu. Rev. Pharmacol. Toxicol. 27:1987;215-235.
19. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Autoradiographic differentiation of μ, δ, and κ opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7:1987;2445-2464.
20. 3H]DAMGO binding to rat brain sections. J. Pharmacol. Exp. Ther. 267:1993;506-514.
21. Martin T.J., Dworkin S.I., Smith J.E. Alkylation of μ opioid receptors by β-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats. J. Pharmacol. Exp. Ther. 272:1995;1135-1140.
22. Martin T.J., Walker L.E., Sizemore G.M., Smith J.E., Dworkin S.I. Within-session determination of dose-response curves for heroin self-administration in rats: comparison with between- session determination and effects of naltrexone. Drug Alcohol Depend. 41:1996;93-100.
23. 35S]GTP-γ-S binding in rat brain sections. Synpase (in press).
24. Negus S.S., Henriksen S.J., Mattox A., Pasternak G.W., Portoghese P.S., Takemori A.E., Weinger M.B., Koob G.F. Effect of antagonists selective for μ, δ, and κ opioid receptors on the reinforcing effects of heroin in rats. J. Pharmacol. Exp. Ther. 265:1993;1245-1252.
25. Pitts R.C., West J.P., Hapke D.M., Morgan D., Dykstra L.A., Picker M.J. Opioids and rate of positively reinforced behavior: II. Antagonism by β-funaltrexamine. Exp. Clin. Psychopharmacol. 4:1996;389-395.
26. Rady J.J., Aksu F., Fujimoto J.M. The heroin metabolite, 6-monoacetylmorphine, activates delta opioid receptors to produce antinociception in Swiss-Webster mice. J. Pharmacol. Exp. Ther. 268:1994;1222-1231.
27. Rothman R.B., Long J.B., Bykov V., Jacobsen A.E., Rice K.R., Holaday J.W. β-FNA binds irreversibly to the opiate receptor complex: in vitro and in vivo evidence. J. Pharmacol. Exp. Ther. 247:1988;405-416.
28. Substance Abuse and Mental Health Services Administration, 1996a. Office of Applied Studies. Advance Report #18: Preliminary estimates from the 1995 National Household Survey on Drug Abuse, From internet site http://www.health.org/pubs/95hhs/ar18txt.htm.
29. Substance Abuse and Mental Health Services Administration, 1996b. Office of Applied Studies. DAWN Advance Report #17: Preliminary estimates from the Drug Abuse Warning Network: preliminary estimates of drug-related emergency department episodes, From internet site http://www.health.org/pubs/96dawn/ar17.htm.
30. Takemori A.E., Portoghese P.S. Affinity labels for opioid receptors. Annu. Rev. Pharmacol. Toxicol. 25:1985;193-223.
31. Takemori A.E., Portoghese P.S. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in β-funaltrexamine-treated mice. J. Pharmacol. Exp. Ther. 243:1987;91-94.
32. Takemori A.E., Larson D.L., Portoghese P.S. The irreversible narcotic antagonistic and reversible agonistic properties of the fumarate methyl ester derivative of naltrexone. Eur. J. Pharmacol. 70:1981;445-451.
33. Tam W.S., Liu-Chen L.-Y. Reversible and irreversible binding of β-funaltrexamine to μ, δ and κ opioid receptors in guinea pig brain membranes. J. Pharmacol. Exp. Ther. 239:1986;351-357.
34. Tempel A., Zukin R.S. Neuroanatomical patterns of the μ, δ and κ opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc. Natl. Acad. Sci. USA. 84:1987;4308-4312.
35. Vaccarino F.J., Bloom F.E., Koob G.F. Blockade of nucleus accumbens opiate receptors attenuates intravenous heroin reward in the rat. Psychopharmacology. 86:1985;37-42.
36. Ward S.J., Portoghese P.S., Takemori A.E. Pharmacological profiles of β-funaltexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation. Eur. J. Pharmacol. 80:1982;377-384.
37. Ward S.J., Fries D.S., Larson D.L., Portoghese P.S., Takemori A.E. Opioid receptor binding characteristics of the non- equilibrium μ antagonist, β-funaltrexamine (β-FNA). Eur. J. Pharmacol. 107:1985;323-330.
38. Weeks J.R. Experimental morphine addiction: methods for automatic intravenous injections in unretrained rats. Science. 138:1962;143-144.
39. Wong C.S., Su Y.F., Watkins W.D., Chang K.J. Opioid agonist binding affinity is increased by magnesium in the presence of guanosine diphosphate but decreased by magnesium in the presence of guanyl-5′-yl-imidodiphosphate. J. Pharmacol. Exp. Ther. 268:1994;653-661.
40. Zernig G., Butelman E.R., Lewis J.W., Walker E.A., Woods J.H. In vivo determination of μ opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharmacol. Exp. Ther. 269:1994;57-65.
41. Zimmerman D.M., Leander J.D., Reel J.K., Hynes M.D. Use of β-funaltrexamine to determine μ opioid receptor involvement in the analgesic activity of various opioid ligands. J. Pharmacol. Exp. Ther. 241:1987;374-378.